Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 10/20 | 0.34 |
| ▸ | TSPO | P30536 | 2/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | PDE5A | O76074 | 2/20 | 0.32 |
| ▸ | MC4R | P32245 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4311738 | 0.95 | PDE10A (0.35) | PDE10ALMNAPDE5AMC4R | |
| SCHEMBL4312044 | 0.90 | PDE10A (0.34) | PDE10ATSPOHCRTR1HCRTR2PDE5A | |
| SCHEMBL4308792 | 0.89 | PDE10A (0.36) | PDE10AHCRTR1HCRTR2PDE5A | |
| SCHEMBL4311454 | 0.85 | PDE10A (0.36) | PDE10APDE5A | |
| SCHEMBL4316031 | 0.85 | PDE10A (0.37) | PDE10APDE5A | |
| SCHEMBL4310984 | 0.83 | PDE10A (0.36) | PDE10ALMNAPDE5A | |
| SCHEMBL4305133 | 0.83 | PDE10A (0.36) | PDE10ALMNAPDE5A | |
| SCHEMBL4320635 | 0.83 | MC4R (0.43) | TSPOMC4RCNR2 | |
| SCHEMBL6047779 | 0.79 | PDE10A (0.35) | PDE10AMC4R | |
| SCHEMBL4312355 | 0.79 | PDE10A (0.37) | PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090062280-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | MERCK SHARP & DOHME CORP. | 2009-03-05 | — | — | US | claimed |
| US-20090062280-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | MERCK SHARP & DOHME CORP. | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062280-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | KCNN3, KCNN1, KCNN2 | PDE10A 219/4885TSPO 859/4885HCRTR1 388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.